PL-100 News
Most Popular PL-100 Story
Merck puts HIV development program on hold
Canada's Ambrilia Biopharma says that Merck has placed the development program for the HIV therapy - MK-8122 - on hold as it focuses on basic science efforts to evaluate other PL-100 prodrugs and Read more...
Latest Headlines
- July 28, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
